Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Multiple Myeloma Diagnosis

Multiple Myeloma Pathophysiology

Multiple Myeloma Treatment

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers-;hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7.

13 Apr 2024

Does IBD affect cancer risk?

Research suggests no strong genetic link between inflammatory bowel disease and increased cancer risk, with specific exceptions in European populations for Crohn's disease and ulcerative colitis.

3 Apr 2024

Venetoclax combo opens new treatment path for incurable multiple myeloma

RCSI research has found that venetoclax, a medication currently approved for leukemia, has benefits for patients with multiple myeloma when used in combination with another drug.

25 Mar 2024

Innovative therapy targets and destroys leukemia stem cells

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells.

26 Feb 2024

Researchers develop enhanced immunotherapy for multiple myeloma treatment

Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor.

14 Feb 2024

Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib's efficacy

A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma."

8 Feb 2024

Study addresses knowledge gap of clinical features and outcomes of Black patients with melanoma

Researchers identified patient- and tumor-level melanoma features in black individuals.

25 Jan 2024

Unintentional weight loss linked to increased risk of cancer diagnosis

Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.

23 Jan 2024

Early warning sign for myeloma found in bone marrow fat cells

A new research perspective was published in Oncotarget's Volume 15 on January 16, 2024, entitled, "Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma."

22 Jan 2024

Antiviral hope emerges as viruses linked to multiple myeloma

A few years ago, a patient was cured of multiple myeloma after being treated for hepatitis C, astounding researchers from the group led by Joaquín Martínez, from the H12O-CNIO Haematological Tumours Clinical Research Unit, a collaboration between the Hospital 12 de Octubre (H12O) and the National Cancer Research Centre (CNIO).

19 Jan 2024

Obesity linked to 73% higher risk of precursor to blood cancer

Individuals with obesity are more likely to have monoclonal gammopathy of undetermined significance (MGUS), a benign blood condition that often precedes multiple myeloma, according to new research published in Blood Advances.

12 Jan 2024

New model predicts individual myeloma risk and treatment response

A multicenter collaboration led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has produced the first computational model for newly diagnosed multiple myeloma that predicts an individual's personalized prognosis based on their tumor genomics and treatments.

9 Jan 2024

Trends in mortality from leading cancers from 2002 to 2019 for the 314 districts in England

Researchers assessed mortality trends in the leading cancers from 2002 to 2019 across 314 districts in England using high-resolution spatiotemporal analysis.

14 Dec 2023

Developing a virtual twin for personalized cancer treatment with CAR-T cell therapy

In recent years, cancer immunotherapies have established themselves as a further pillar of medical oncology alongside traditional treatment options (surgery, radiotherapy and chemotherapy).

13 Dec 2023

Study: Risk of dying from cancer depends on where you live in England

The risk of dying from the 10 forms of cancer with the largest death toll for men and women varies massively depending on the district in England where people live, according to a study published in The Lancet Oncology.

11 Dec 2023

New drug combo shows promise in targeting RAS-mutant multiple myeloma

The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.

11 Dec 2023

Exploring associations between BMI, cardiometabolic diseases, and cancer risk

Researchers evaluate the associations of body mass index, type 2 diabetes, and cardiovascular disease with cancer risk.

29 Nov 2023

Genome study unveils genetic ties between cannabis use disorder and lung cancer risk

A genome-wide association study in Nature Genetics reveals insights into the genetics of cannabis use disorder, highlighting its strong association with psychopathology and a causal link to lung cancer, and suggesting distinct genetic pathways from mere cannabis use.

23 Nov 2023

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

In this Interview, Dr. Fang-Yi Chu talks to NewsMed about the role of transmembrane proteins in targeting oncology research.

From Sino Biological Inc. 23 Nov 2023

CMA clarifies cooperation on combination therapies to speed up patient access to vital treatments

The Competition and Markets Authority (CMA) has today issued a statement clarifying that certain types of engagements between competing drug firms working on 'combination therapies' will not be prioritized for investigation - making it easier for drug firms to work together to develop vital treatments for use in the NHS.

17 Nov 2023